Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.65 |
| ▸ | FBP1 | P09467 | 2/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756053 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL18041457 | 0.84 | NFE2L2 (0.58) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL18041456 | 0.84 | NFE2L2 (0.58) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL15498134 | 0.84 | NFE2L2 (0.89) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL4632192 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL6158116 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL3028232 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL2770622 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL3028231 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL4632191 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| US-4308273-A | 1,6-Naphthyridine derivatives, and antidinic and cerebral circulation improver containing such derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | NFE2L2 3378/4885FBP1 246/4885VCP 3966/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | NFE2L2 3378/4885FBP1 246/4885VCP 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.